My brother’s oncologist at Moffitt recently told us that they are no longer accepting patients into their anti-PD1 trials unless and until the patient has tried and failed ipi (Yervoy). Has anyone else heard this? Does anyone know why this should be the case? On the face of it, it seems to be a very odd requirement.
This is just for this specific trial. They are testing out the population that failed IPI, of which there are a good number, to see how they respond to another immunotherapy. Many of the other trials excluded prior IPI use which in fact was not useful for the patient population. So I see this as a positive thing.